Jacques Theurillat

    Partner, Crossover Strategy

    Jacques joined us in 2017 and brings the Crossover team his extensive experience in biopharmaceutical company operations, as well as his know-how when it comes to making private and public investments.

    His experience in building a team of international investors to deploy a new strategy is also important for the Crossover team. He is expected to take positions on the board of some of the public companies in which the Fund will invest.

    Jacques co-founded in 2008 and managed Ares Life Sciences, a privately owned investment fund with the objective to build and manage a portfolio of companies in life sciences. Jacques built a new team of 9 professionals and invested €1.25 billion in six public and private companies including Euromedic International BV, Esaote Spa, Bronchus Technologies Inc, Santhera Pharmaceuticals, Stallergenes SA, Greer Inc. In June 2015, Stallergenes and Greer merged creating the worldwide market leader in Allergy Immunotherapy.

    Jacques had previously spent almost 20 years in the Serono pharmaceutical group, where he was deputy CEO and senior executive vice president for strategic corporate development, responsible for Serono’s global strategy and in-licensing initiatives. Jacques also served as Serono’s president of European and international sales & marketing and CFO. In his various roles at Serono, Jacques was responsible for several major equity financings of the company, including the $2 billion listing on the NYSE in 2000, one of the largest-ever biotech secondary offerings worldwide. Jacques was also involved in the process that led to the sale of the company to Merck KGA for 14 billion Swiss Francs.

    Jacques is a Swiss barrister and holds Bachelor of Law degrees from both Madrid University and Geneva University. He also holds a Swiss Federal Diploma (Tax Expert) and has a Master’s degree in Finance.



    "For the companies we invest in, we spend months looking at clinical programs, intellectual property, manufacturing, management, the board, every detail. Absolutely, the Sofinnova Partners network helps with all of this."

    Sector

    Biopharmaceuticals

    Join our mailing list

    Keep up to date with our latest news.

    Required
    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.